Is CaMKII equally responsible for inducing sarcoplasmic reticulum Ca2+ leak in human ischemic and dilated cardiomyopathy?
CaMKII inhibition may be a beneficial therapeutic strategy for the majority of heart failure patients, regardless of whether the etiology is ischemic or dilated cardiomyopathy.
Functional and molecular measures of the SR Ca(2+) leak are comparable in human ICM and DCM. CaMKII is equally responsible for the induction of the 'RyR2 leakiness' in both pathologies. Thus, CaMKII inhibition as a therapeutic measure may not be restricted to patients suffering from DCM but rather may be beneficial for the majority of HF patients.
Fischer et al. (Mon,) studied this question.